Cannabis Clinical Trials

The Food and Drug Administration will not tolerate companies peddling marijuana-based products to treat cancer—at least, not without better evidence. The agency sent four warning letters on Tuesday to companies selling products online with health claims about cancer, including that the products could stop tumors from growing. Products that were being sold include cannabidiol (CBD) oil, […]

by

By Alicia Wallace, The Cannabist Staff A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the […]

by

OTTAWA, ONTARIO–(Marketwired – Oct. 26, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis […]

by

The Food and Drug Administration (FDA) has a message for companies trying to hawk marijuana-based products as ones that can “prevent, diagnose, treat, or cure cancer” with zero evidence supporting that assertion: Knock it off, immediately. “Substances that contain components of marijuana will be treated like any other products that make unproven claims to shrink […]

by

The FDA has said it is increasingly concerned about unapproved cannabis and related products that claim to prevent, diagnose and even cure cancer. In a strongly-worded statement the FDA said it had sent warning letters to four companies warning that their actions are against US laws and put patients at risk by preventing them accessing […]

by

Visit the MPX Bioceutical Corporation Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors. Election of Board of Directors Appoint Deloitte LLP as Auditor Appointment of Officers Issuance of Stock Options Entering into Executive Services Agreement with Canadian Capital, LLC TORONTO, Nov. 02, 2017 (GLOBE NEWSWIRE) […]

by

New data published by Verify Markets, states that the wholesale legal cannabis market in the U.S was valued at $210.7 million in 2016. The increased legalization efforts in the November 2016 elections resulted in more states approving cannabis legislation in some form, i.e., medical or recreational. Recreational initiatives were approved in California, Massachusetts, Nevada, and Maine while medical cannabis was legalized in Arkansas, Florida, […]

by

Greetings, readers! This is Sy. The Food and Drug Administration (FDA) has a message for companies trying to hawk marijuana-based products as ones that can “prevent, diagnose, treat, or cure cancer” with zero evidence supporting that assertion: Knock it off, immediately. “Substances that contain components of marijuana will be treated like any other products that […]

by

CannPal Animal Therapeutics Ltd (ASX:CP1) has been granted an authorisation to possess and supply cannabis for scientific research by the New South Wales Ministry of Health. The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985. Importantly, the permit allows CannPal to apply for permits to import cannabis for […]

by

The Canadian Securities Exchange (“CSE“) recently announced the introduction of the CSE25 Index, comprised of the securities of the largest companies trading on the exchange. The CSE25 Index is a subgroup of the CSE Composite Index. The composite index launched in 2015 and includes almost half of the exchange’s listed companies and, according to the […]

by